| Literature DB >> 32019094 |
Sarah Ronan1, Nicola Shannon2, Katie Cooke2, Trish McKeon2, Elaine K Walsh3, Alan Kearney4, Laura J Sahm1,5.
Abstract
Medication review (MR) is a vital part of the pharmacist's role in hospital. However, in the South Infirmary Victoria University Hospital (SIVUH), Cork, Ireland, this has not been fully implemented due to resource issues. In addition, the cost of providing this service has not been evaluated. Moreover, it is not clear how other members of the multidisciplinary team e.g. Nurses, value any interventions made as a result of the MR. This mixed methods study assessed the impact of MR in terms of (i) potential clinical harm, (ii) cost avoidance and (iii) the views of nursing staff on the role of the pharmacist. The setting is a 192-bed, voluntary, acute hospital, in the Munster region of Ireland. Study I: The pharmacist provided MR to patients conventionally once a week. Any interventions were then assessed for potential clinical harm and to calculate cost avoidance. Study II: Semi-structured interviews, guided by a topic guide were completed with 12 nurses (11 female). Thematic analysis was used to code the main themes. Main outcome measure: To estimate the cost, cost avoidance, and the net cost benefit ratio of MR provided by pharmacists. Study I: Of 128 patients who received the MR, 113 interventions were made. The estimated cost of providing the MR was €2,559 (senior pharmacist). Using €1084 as the cost of an adverse drug event (ADE), the cost avoidance was calculated at €42,330. This led to a net cost benefit of €39,771 (senior pharmacist) which equated to a net cost benefit ratio of 16.5:1. Study II: The main themes were (i) perceptions of pharmacy services, (ii) the role of the pharmacist-past, present and future, and (iii) teamwork and communication. Nurses expressed a desire to have more pharmacists present on the wards.Entities:
Keywords: adverse drug events; cost avoidance; cost benefit ratio; medication review; semi-structured interviews; views of nurses
Year: 2020 PMID: 32019094 PMCID: PMC7151682 DOI: 10.3390/pharmacy8010014
Source DB: PubMed Journal: Pharmacy (Basel) ISSN: 2226-4787
Interpretation of Kappa measure of agreement [25,29].
| Kappa Measure of Agreement | Interpretation |
|---|---|
| <0 | Poor agreement |
| 0.0–0.20 | Slight agreement |
| 0.21–0.40 | Fair agreement |
| 0.41–0.60 | Moderate agreement |
| 0.61–0.80 | Substantial agreement |
| 0.81–1.00 | Almost perfect agreement |
Probability scores for assessment of potential clinical harm of the PIs provided to the raters.
| Probability of an ADE Occurring | Probability Score | Example |
|---|---|---|
| No harm expected | 0 | Pharmacist suggest changing a patient from esomeprazole to omeprazole for economic reasons |
| Very low | 0.01 | Patient regularly takes a bisphosphonate, but medication omitted from drug kardex |
| Low | 0.1 | Patient takes an antibiotic twice a day, when the recommended dose would be three times a day |
| Medium | 0.4 | Metformin dose not reduced despite patient demonstrating renal impairment |
| High | 0.6 | Patient prescribed amiodarone while taking digoxin without any reduction in digoxin dose |
Demographics of patients with PIs.
| Demographic | Description | Patients with PI(s) |
|---|---|---|
| Gender (n) | Male | 36 (61%) |
| Female | 23 (39%) | |
| Specialty (n) | Medicine | 3 (5.1%) |
| Surgery | 56 (94.9%) | |
| Age (years) | Median | 70 |
| Interquartile range | 23 | |
| Regular medicines | Median | 11 |
| IQR | 6 | |
| PRN medicines | Median | 4 |
| IQR | 3 |
Abbreviations: PI(s): pharmacist intervention(s); n: number of patients; IQR: interquartile range; PRN: “as required”.
Types and prevalence of PIs.
| Type of PI | No. of PIs (%) |
|---|---|
|
|
|
|
|
|
| Incorrect frequency | 11 (9.7%) |
| Incorrect dose | 4 (3.5%) |
| Incorrect formulation | 1 (0.9%) |
| Incorrect drug and dose | 1 (0.9%) |
| Incorrect drug and strength | 1 (0.9%) |
|
|
|
| Co-prescribe same drug | 10 (8.6%) |
| Co-prescribe same drug class | 8 (7.1%) |
|
|
|
| Frequency of administration unclear | 7 (6.2%) |
| Dose charted unclear | 6 (5.3%) |
| Drug charted unclear | 4 (3.5%) |
|
|
|
| More than licensed dose | 6 (5.3%) |
| Less than licensed dose | 2 (1.8%) |
|
|
|
|
|
|
| Pharmacokinetic | 3 (2.7%) |
| Pharmacodynamic | 3 (2.7%) |
|
|
|
|
|
|
| Less than licensed frequency | 2 (1.8%) |
|
|
|
Abbreviations: PI: pharmacist intervention; PIs: pharmacist interventions. 1 Drug kardex was checked for errors using admission notes and/or contacting community pharmacy and/or contacting general practitioner. 2 As per Summary of Product Characteristics. 3 As per British National Formulary 75 [35]. 4 As per Lexicomp® Drug Interactions checker [36]. Terms in bold are the main headings, and underneath are specific examples.
Types and prevalence of medicines associated with PIs.
| ATC Code | Medicine Type | Frequency Identified 1 (%) |
|---|---|---|
| N02 | Analgesics | 17 (11.2%) |
| N06 | Psychoanaleptics | 15 (9.9%) |
| M01 | Anti-inflammatory and anti-rheumatic products | 13 (8.6%) |
| A11 | Vitamins | 13 (8.6%) |
| R03 | Drugs for obstructive airway diseases | 12 (7.9%) |
| N05 | Psycholeptics | 9 (5.9%) |
| A12 | Mineral supplements | 8 (5.3%) |
| C10 | Lipid modifying agents | 6 (4.0%) |
| C03 | Diuretics | 5 (3.3%) |
| Others | Others | 54 (35.5%) |
Abbreviation: ATC: Anatomical Therapeutic Chemical Classification System. 1 Some of the interventions involved multiple medicines, for example duplication of drugs within the same drug class would be counted as two medicines.
Examples of PIs and assigned median probability scores.
| Probability of an ADE Occurring | Median Probability Score | Example |
|---|---|---|
| No harm expected | 0 | Medication reconciliation completed. Omission of Decavit plus® tablets (multivitamin) on kardex. |
| Very low | 0.01 | Duplication of Movicol® (macrogol) sachets on kardex. |
| Low | 0.1 | Durogesic® (fentanyl) patch 50 micrograms/72 h prescribed. Error in calculation of timing of application of patch on kardex and the patch was applied one day late. |
| Medium | 0.4 | Overdose of Keral® (dexketoprofen), prescribed orally 50 mg three times daily, maximum daily oral dose is 75 mg a day i.e., double the maximum daily dose was prescribed. |
| High | 0.6 | Xarelto® (rivaroxaban) and Innohep® (tinzaparin) prescribed at the same time on kardex. |
Abbreviation: ADE: Adverse drug event.